Papers: 10.1371/journal.ppat.1009427

https://doi.org/10.1371/journal.ppat.1009427

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

Cited by: 33
Author(s): Pierre Bessière, Marine Wasniewski, Evelyne Picard-Meyer, Alexandre Servat, Thomas Figueroa, Charlotte Foret‐Lucas, Amelia Coggon, Sandrine Lesellier, Frank Boué, Nathan Cebron, Blandine Gausserès, Catherine Trumel, Gilles Foucras, Francisco J. Salguero, Élodie Monchâtre-Leroy, Romain Volmer
Published: almost 4 years ago

Software Mentions 1